Novo Nordisk to replace CEO Lars Jorgensen amid stiff competition in obesity drug market; stock down 33% YTD

The Novo Nordisk Foundation started a dialog with Novo’s board “on the merits of an accelerated CEO succession,” Novo said, adding that the move was a joint decision.

Markets